Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Asset Writedowns and Impairment: 2010-2015

Historic Asset Writedowns and Impairment for Ligand Pharmaceuticals (LGND) over the last 3 years, with Mar 2015 value amounting to $2.4 million.

  • Ligand Pharmaceuticals' Asset Writedowns and Impairment rose 2103.67% to $2.4 million in Q1 2015 from the same period last year, while for Mar 2015 it was $5.6 million, marking a year-over-year increase of 812.23%. This contributed to the annual value of $1.3 million for FY2015, which is 58.93% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Asset Writedowns and Impairment stood at $2.4 million for Q1 2015, which was down 26.36% from $3.3 million recorded in Q4 2014.
  • Ligand Pharmaceuticals' Asset Writedowns and Impairment's 5-year high stood at $3.3 million during Q4 2014, with a 5-year trough of -$770,000 in Q3 2013.
  • Over the past 3 years, Ligand Pharmaceuticals' median Asset Writedowns and Impairment value was $111,500 (recorded in 2013), while the average stood at $748,625.
  • Examining YoY changes over the last 5 years, Ligand Pharmaceuticals' Asset Writedowns and Impairment showed a top increase of 12,530.00% in 2013 and a maximum decrease of 122.32% in 2013.
  • Quarterly analysis of 4 years shows Ligand Pharmaceuticals' Asset Writedowns and Impairment stood at $977,000 in 2012, then crashed by 88.33% to $114,000 in 2013, then skyrocketed by 2,761.40% to $3.3 million in 2014, then surged by 2,103.67% to $2.4 million in 2015.
  • Its Asset Writedowns and Impairment was $2.4 million in Q1 2015, compared to $3.3 million in Q4 2014 and -$125,000 in Q2 2014.